Recurrent Glioblastoma Clinical Trial - ReSPECT-GBM

Cancer research · Glioblastoma

The ReSPECT-GBM trial investigates the safety and efficacy of REYOBIQTM (rhenium Re186 obisbemeda) as a targeted radiolabeled therapy for recurrent glioblastoma.

Recurrent glioblastoma has limited treatment options and a poor prognosis, underscoring the need for novel therapeutic strategies.

Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.

Original source

Related signals

• Phase 2b Trial for Cancer Vaccine in Newly Diagnosed Glioblastoma Will Continue
• Glioma
• Glioblastoma Clinical Trials for New Treatments
• Clinical trial links oncolytic immunoactivation to survival in glioblastoma
• Tumour treating fields therapy for glioblastoma: current advances and future directions